FDA considers new deputy commissioner roles as Trump prepares to announce additional MFN drug pricing agreements
read at raps ↗RegulatoryNeutral
The Food and Drug Administration is evaluating the establishment of new deputy commissioner positions to support its expanding portfolio of responsibilities.
The proposal reflects ongoing efforts to strengthen the agency’s leadership structure as it navigates a complex regulatory environment.
At the same time, former President Donald Trump is expected to reveal further mutually favored nation (MFN) drug pricing agreements, signaling continued attention to pharmaceutical pricing policy.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals”
read at raps ↗
comments(0)
5-min edit window · permanent after that